Oxytocin

Peripherally, oxytocin drives uterine contraction and milk letdown, which is its licensed use. Centrally, oxytocin receptors in the amygdala, striatum and hypothalamus modulate social behaviour: imaging studies consistently show reduced amygdala response to threatening faces after intranasal dosing, and behavioural studies show increased trust, eye contact and in-group affiliation. It also cross-reacts with vasopressin V1a receptors, which complicates clean interpretation of any given effect. The awkward truth is that how much intranasally administered oxytocin actually reaches the brain remains contested - Leng and Ludwig's critique argues that the plasma and CSF concentrations achieved are too low to explain the reported behavioural effects, and the field has a well-documented replication problem.

Targets: Oxytocin receptor (OXTR), Vasopressin V1a receptor (cross-reactivity), Amygdala threat circuitry, Nucleus accumbens dopamine signalling

• · 24 IU is the near-universal research dose and equals roughly 40 mcg; 40 IU is about 67 mcg. Dosing is conventionally expressed in international units - 1 IU is approximately 1.7 mcg. Split between nostrils and sniff gently rather than hard, which drives it down the throat instead.
• · Compounding pharmacies commonly supply 10-100 IU troches. Absorption by this route is poorer and less predictable than intranasal, and central penetration is even more speculative.

Work out your exact syringe units →

• commonNasal irritation or a burning sensation
• commonHeadache
• uncommonEmotional lability or unexpected tearfulness— Not always unwelcome, but worth knowing about before a meeting.
• uncommonIncreased in-group bias, envy or defensiveness— A well-replicated finding. Oxytocin is not a universal kindness molecule; it sharpens the line between us and them.
• uncommonUterine cramping— Relevant to anyone with a uterus, and the reason it is a labour-induction drug.
• rareHyponatraemia and water retention— Oxytocin has antidiuretic activity at high doses. Serious hyponatraemia has occurred with high-dose intravenous use combined with large fluid volumes - not a realistic risk at 24 IU intranasally, but it is why the dose matters.

• Pregnancy - oxytocin induces uterine contractions and is a labour-induction drug. This is the single most important contraindication on this page.
• Known hyponatraemia or SIADH.
• Significant cardiovascular disease at high or intravenous doses.
• Do not use it as a treatment for autism on the basis of the mechanism - the large SOARS-B trial found no benefit.

• synergypt-141 — Commonly stacked for libido and emotional connection through different receptor systems. Both can cause nausea and flushing.
• synergyselank — Both used intranasally for social anxiety; no known conflict.
• synergykisspeptin-10 — Overlapping effects on sexual and emotional brain processing.

• · Sodium if you are using high doses with large fluid intake - unlikely to matter intranasally, but it is the one lab that can go wrong.
• · Blood pressure at higher doses.
• · Pay attention to whether social effects are actually improving over weeks; if they are fading, you are downregulating and should stop.

Approved worldwide as a prescription obstetric drug. Intranasal use for social cognition is off-label everywhere; research-grade powder is sold as a research chemical, and compounded nasal sprays are available by prescription in some countries.

• Sikich et al. 2021, intranasal oxytocin in children and adolescents with autism spectrum disorder (SOARS-B), New England Journal of Medicine (trial)
• Leng & Ludwig 2016, intranasal oxytocin: myths and delusions, Biological Psychiatry (review)
• Kosfeld et al. 2005, oxytocin increases trust in humans, Nature (trial)

The mechanism is well understood; the delivery is not, and that gap is the whole story of this compound. Centrally, oxytocin receptors in the amygdala, striatum and hypothalamus modulate social behaviour, and the most replicated finding is reduced amygdala response to threatening faces after intranasal dosing, alongside behavioural effects on trust, eye contact and in-group affiliation. It cross-reacts at vasopressin V1a receptors, which differ from oxytocin at only two positions - so any given behavioural effect may not be an oxytocin receptor effect at all, and that ambiguity is rarely acknowledged in popular accounts. Now the uncomfortable part. Leng and Ludwig's critique argues that very little of the large amounts applied intranasally reaches cerebrospinal fluid, while peripheral concentrations rise to supraphysiological levels - meaning the most reliably achieved effect of an intranasal dose is a peripheral one. The direct measurement supports the shape of that argument: CSF levels do rise significantly, but slowly, over 75 minutes, and with essentially no correlation to plasma. Since most experimental paradigms test at 30-45 minutes, a substantial part of the behavioural literature was measuring at a time when CSF oxytocin had not yet risen. That does not prove the effects are peripheral or placebo, but it is a serious problem that the field has not resolved, and it sits alongside a well-documented replication crisis and the flatly negative SOARS-B trial. The honest position is that real central effects probably exist and are smaller and more context-dependent than the popular account, and that the dose-response relationship is unknown in a way that makes higher dosing actively unwise.

The commonest failure is chronic use. Daily intranasal oxytocin has been associated with receptor downregulation and a blunting of the social response over time, which is exactly the opposite of the intended effect and develops slowly enough that people escalate rather than stop. Use it intermittently. The second is dose escalation on the assumption that more is better: higher doses are not more prosocial and in some studies flip the effect, increasing in-group bias, envy and defensive aggression - oxytocin sharpens the line between us and them rather than dissolving it, and that is a well-replicated finding. The third is technique: sniffing hard drives the spray past the nasal mucosa into the throat, which is the one part of the delivery you actually control and the part most people get wrong. The fourth is unit confusion - research powder is sold in milligrams, dosing is discussed in IU, and 1 IU is roughly 1.7 mcg. Do the arithmetic before filling the bottle. The fifth is storage: oxytocin in solution degrades noticeably at room temperature, which is why pharmaceutical nasal sprays are refrigerated. Sixth, and worth stating plainly, is expectation: the compound is real, the effect is smaller and more context-dependent than the popular account, and a substantial fraction of what people report is the situation they engineered around taking it.

1. 40 mcgFirst use — 24 IU, approximately 40 mcg, split between nostrils. Sniff gently rather than hard - a hard sniff drives the spray past the nasal mucosa and down the throat, which is the opposite of what you want. This is the near-universal research dose and there is no good reason to start anywhere else.
2. 67 mcgOccasional use — 40 IU, approximately 67 mcg. Worth knowing that higher doses are not more prosocial and in some studies flip the effect, increasing in-group bias and defensive aggression rather than warmth. This is a ceiling, not a target.
3. —Not recommended — There is no step 3. The dose-response relationship for the social effects is not monotonic and may be inverted at higher doses, and the one serious adverse outcome available - hyponatraemia - is dose-dependent. Escalating beyond 40 IU has no supporting rationale.

• Oxytocin receptor (OXTR) — High-affinity Gq-coupled GPCR; specific Kd not verified here

  Uterine contraction and milk letdown peripherally. Centrally, amygdala, striatal and hypothalamic signalling underlying the social effects - reduced amygdala threat reactivity being the most replicated.

• Vasopressin V1a receptor — Meaningful cross-reactivity - oxytocin and vasopressin differ at only two of nine positions

  Confounds interpretation of every behavioural finding. V1a signalling has its own effects on social behaviour, aggression and vasoconstriction, and no intranasal study can cleanly separate the two.

• Amygdala threat circuitry — Downstream

  Reduced amygdala response to threatening faces on functional imaging. The most consistent neuroimaging finding in the field.

• Nucleus accumbens dopamine signalling — Downstream

  Increased salience of social cues, which is the mechanism most often invoked for the trust and affiliation effects - and also for the finding that oxytocin increases in-group bias and defensive aggression rather than universal warmth.

• SOARS-B - Study of Oxytocin in Autism to improve Reciprocal Social Behaviors Phase 2, randomised, double-blind, placebo-controlled · n=290 · 24 weeks · 2021

  Change from baseline in the Aberrant Behavior Checklist modified Social Withdrawal subscale (ABC-mSW) in children and adolescents aged 3-17 with autism spectrum disorder, at a target daily dose of 48 IU intranasally. Flatly negative: least-squares mean change -3.7 with oxytocin against -3.5 with placebo, p=0.61. Secondary outcomes on social and cognitive function showed no meaningful between-group differences and adverse event profiles were comparable. 355 screened, 290 enrolled (146 oxytocin, 144 placebo).

• Oxytocin increases trust in humans (Kosfeld et al.) Experimental, double-blind, placebo-controlled · 2005

  Investor behaviour in a trust game after intranasal oxytocin versus placebo. Reported a substantial increase in trusting behaviour. This is the single most influential study in the field, published in Nature in 2005, and it is also the paradigm case for the replication problems that followed.

Plasma oxytocin plateaus at about 15 minutes after intranasal dosing and falls after 60. Cerebrospinal fluid levels take up to 75 minutes to rise significantly, and the two compartments do not correlate. Most experimental paradigms test effects at 30-45 minutes - which is the conventional wisdom for timing a dose, and which is also, on the CSF data, before central levels have risen. That tension is unresolved. Practically, dose 45 minutes before the situation you care about, which is what the literature does, and be aware that the effect window most studies describe runs roughly 30 minutes to 2 hours. Plasma half-life is 3-6 minutes, so nothing here is explained by circulating peptide.

PT-141 plus oxytocin is the common libido-and-connection stack, running through unrelated receptor systems with no known pharmacological conflict - though both cause nausea and flushing and the effects are additive in that direction. Selank pairs with it sensibly for social anxiety: neither sedates, the mechanisms do not overlap, and both are intranasal, which means you are irritating the same mucosa twice in a session. Kisspeptin-10 overlaps on sexual and emotional brain processing. The important interaction is not with another peptide at all - it is with fluid intake. Oxytocin has antidiuretic activity, and the documented serious harm from this molecule is hyponatraemia from high doses combined with large fluid volumes. If you are using it around endurance exercise, MDMA, or anything else that drives you to drink a lot of water, that combination is the one with a real mechanism behind it. The single most important contraindication remains pregnancy: this is a labour-induction drug, and no stacking consideration outranks that.

Against the other social-and-mood peptides here: Selank has one small Russian trial and works on arousal; oxytocin has an enormous randomised literature that is also a textbook case of publication bias and failed replication, plus one large definitive negative trial in autism. Neither of those is a strong evidential position, but they fail in different directions - Selank is under-studied, oxytocin is over-studied and unresolved. Against alcohol, which is what oxytocin is functionally competing with for most people: alcohol is more reliable, more socially available and considerably worse for you. Against actually treating social anxiety with exposure-based therapy or an SSRI: those have replicated evidence and durable effects; oxytocin is a situational tool at best. The specific thing oxytocin has that nothing else here has is an approved pharmaceutical form with a long safety record - it is a real drug used in obstetrics worldwide, and the safety profile at intranasal doses is genuinely well characterised even where the efficacy is not. The specific thing it lacks is any confidence that the intranasal route delivers a meaningful amount to the brain.

$15–$80/month. Research-grade powder is cheap - a 5 mg vial typically runs 30-60 USD, which at 40 mcg per use is over 100 doses. For intermittent use that is a few dollars a month. Compounded prescription nasal sprays, available in some countries, cost considerably more, typically 60-150 USD monthly, and buy you a formulation that is actually made for nasal delivery and stored correctly. Given how much of this compound's uncertainty is a delivery problem, that is not a trivial difference.

• ?How much intranasally administered oxytocin reaches the brain remains genuinely contested. CSF levels do rise but slowly and modestly, with no correlation to plasma.
• ?The mismatch between the 75-minute CSF rise and the 30-45 minute testing window used by most behavioural studies has not been resolved and may mean much of the literature was measuring something other than central oxytocin.
• ?Volume of distribution, protein binding and clearance figures for intranasal dosing are not established.
• ?The dose-response relationship for social effects is unknown and may be non-monotonic. Higher is demonstrably not better and may be worse.
• ?How much of the behavioural literature survives the replication crisis is unsettled. Kosfeld 2005 in particular has a complicated replication history.
• ?V1a cross-reactivity means no intranasal study can cleanly attribute an effect to the oxytocin receptor.
• ?Participant numbers in Kosfeld 2005 I did not verify.
• ?The receptor downregulation reported with chronic daily use is consistently described but I could not resolve a definitive primary characterisation of its timecourse or reversibility.
• ?The claim that sublingual or buccal routes achieve useful central exposure is speculative and less supported than the intranasal route, which is itself contested.

• Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder Sikich L, Kolevzon A, King BH, McDougle CJ, Sanders KB, Kim SJ, Spanos M, Chandrasekhar T, Trelles MDP, Rockhill CM, Palumbo ML, Witters Cundiff A, Montgomery A, Siper P, Minjarez M, Nowinski LA, Marler S, Shuffrey LC, Alderman C, Weissman J, Zappone B, Mullett JE, Crosson H, Hong N, Siecinski SK, Giamberardino SN, Luo S, She L, Bhapkar M, Dean R, Scheer A, Johnson JL, Gregory SG, Veenstra-VanderWeele J, New England Journal of Medicine, 2021 · PMID 34644471

  The large, well-run, definitively negative trial. 290 children, 24 weeks, 48 IU daily, no difference from placebo on the primary or any secondary outcome. The most important single result in the intranasal oxytocin literature.

• Intranasal Oxytocin: Myths and Delusions Leng G, Ludwig M, Biological Psychiatry, 2016 · PMID 26049207

  The critique that reframed the field. Argues that very little of what is applied intranasally reaches cerebrospinal fluid while peripheral levels go supraphysiological, and calls for preregistration, transparent outcome reporting and proper dose-response studies. Read this before believing anything about intranasal oxytocin, including things on this page.

• Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans Striepens N, Kendrick KM, Hanking V, Landgraf R, Wullner U, Maier W, Hurlemann R, Scientific Reports, 2013 · PMID 24310737

  The direct measurement. 24 IU intranasally in 11 participants: plasma plateaus at 15 minutes and falls after 60, CSF takes 75 minutes to rise significantly, and the two compartments barely correlate. This is the single most practically useful pharmacokinetic paper on the compound and it implies most behavioural studies tested too early.

• Oxytocin increases trust in humans Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E, Nature, 2005 · PMID 15931222

  The study that started the entire intranasal oxytocin field. Included because it is foundational and because its subsequent replication history is the reason the field is where it is.